UC Riverside's Mahsa Khayat-Khoei presented TriNetX data on 339,092 MS patients at MSToronto2026. She says prospective trials are still needed to show any real protective effect.
Recap by typeshit. Full story at MedPage Today.
The Scientist weighs whether GLP-1 drugs could lengthen life and finds the answer still unsettled. Tap through for where the research stands.
The review covers 47 peptides from meat, leather and seafood waste and cites a 12-trial meta-analysis showing a systolic drop of about 5 mmHg, credited to the authors.
Researchers think orexin drugs could expand into ADHD and fatigue the way GLP-1s grew past diabetes. Alkermes reported early ADHD results in 50 adults.
Researchers report in Amino Acids that the peptide blocks HMGA2 at the IL6 promoter in a cell model. The authors note the work is cell culture only, far from any human use.
9:33
A short clip from Dr. Jones DC on what he sees as the pros, cons and errors people make with the experimental drug retatrutide.
36:24
DOWNSIZED covers effects of the experimental triple agonist retatrutide other than weight loss, as the channel describes them.
Loading…